NCT00000773View on ClinicalTrials.gov

Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 1996

Conditions

Pneumonia, Pneumocystis CariniiHIV Infections

Interventions

DRUG

Atovaquone

Trial Locations (6)

38105

St. Jude/UTHSC CRS, Memphis

60614

Chicago Children's CRS, Chicago

94143

UCSF Pediatric AIDS CRS, San Francisco

Unknown

Tulane/LSU Maternal/Child CRS, New Orleans

DUMC Ped. CRS, Durham

00936

Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000773 - Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children | Biotech Hunter | Biotech Hunter